Krina K. Patel, MD, MSc

home / authors / krina-k-patel-md-msc

Articles

Unmet Needs in R/R MM and Clinical Practice Pearls

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 16th 2023

Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.

Case 3: Sequencing BCMA-Directed Therapies for R/R MM

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 16th 2023

Krina Patel, MD, MSc, presents the case of a 65-year-old woman with relapsed/refractory multiple myeloma, and the panel discusses the optimal sequencing of her treatment regimens.

Selecting the Appropriate CAR T-Cell Therapy in R/R MM

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 9th 2023

Drs Krina Patel and Hana Safah explain their impressions of the data on BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma and its potential impact on clinical practice.

CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 9th 2023

Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.

Case 2: Treatment of R/R MM with BCMA-Directed CAR T-Cell Therapy

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 2nd 2023

Hana Safah, MD, presents the case of a 63-year-old woman with relapsed/refractory multiple myeloma receiving treatment with a BCMA-directed CAR T-cell therapy.

DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

March 2nd 2023

Sagar Lonial, MD, FACP, reviews the design and outcomes of the DREAMM-2 and ALGONQUIN studies investigating belantamab mafodotin in the treatment of relapsed/refractory multiple myeloma.

Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 23rd 2023

The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.

Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 23rd 2023

Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.

Selecting Patients with R/R MM for Treatment With Bispecifics

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 17th 2023

Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.

MajesTEC-1: Teclistamab in R/R MM Treatment

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 17th 2023

A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.

Case 1: Treatment of R/R MM with a BCMA-Directed Bispecific Antibody

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 9th 2023

Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.

$Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)$

Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)

Sagar Lonial, MD, FACP;Krina K. Patel, MD, MSc;Hana Safah, MD

February 9th 2023